| 14th Nov 2022 7:00 am |
RNS |
Lynparza combo recommended in the EU for mCRPC |
| 11th Nov 2022 7:00 am |
RNS |
Imfinzi + Imjudo approved in US for lung cancer |
| 10th Nov 2022 7:00 am |
RNS |
YTD and Q3 2022 Results |
| 9th Nov 2022 7:00 am |
RNS |
FDA Advisory Committee recommends PT027 in asthma |
| 4th Nov 2022 7:00 am |
RNS |
Beyfortus (nirsevimab) approved in EU |
| 1st Nov 2022 3:00 pm |
RNS |
Total Voting Rights |
| 26th Oct 2022 7:00 am |
RNS |
Capivasertib Phase III trial met primary endpoints |
| 25th Oct 2022 7:00 am |
RNS |
Update on MESSINA Phase III trial |
| 24th Oct 2022 7:00 am |
RNS |
Imfinzi + Imjudo approved in advanced liver cancer |
| 3rd Oct 2022 3:00 pm |
RNS |
Total Voting Rights |
| 30th Sep 2022 10:30 am |
RNS |
Board Committee Changes |
| 27th Sep 2022 7:05 am |
RNS |
Koselugo approved in Japan for NF1 |
| 27th Sep 2022 7:00 am |
RNS |
Tezspire approved in Japan for severe asthma |
| 23rd Sep 2022 7:00 am |
RNS |
Ultomiris approved in EU for gMG |
| 23rd Sep 2022 7:00 am |
RNS |
Ultomiris approved in EU for gMG |
| 22nd Sep 2022 7:00 am |
RNS |
Lynparza approved in China for ovarian cancer |
| 21st Sep 2022 7:00 am |
RNS |
Tezspire approved in the EU for severe asthma |
| 20th Sep 2022 7:00 am |
RNS |
Evusheld approved in EU for COVID-19 treatment |
| 16th Sep 2022 7:10 am |
RNS |
Danicopan Phase III trial met primary endpoint |
| 16th Sep 2022 7:05 am |
RNS |
Evusheld positive CHMP opinion in EU |
| 16th Sep 2022 7:00 am |
RNS |
Nirsevimab recommended for approval in EU by CHMP |
| 5th Sep 2022 7:05 am |
RNS |
Forxiga approved in China for CKD |
| 5th Sep 2022 7:00 am |
RNS |
Imfinzi approved in US for biliary tract cancer |
| 1st Sep 2022 3:00 pm |
RNS |
Total Voting Rights |
| 30th Aug 2022 1:00 pm |
RNS |
Evusheld approved for COVID-19 in Japan |
| 30th Aug 2022 7:01 am |
RNS |
Farxiga shows CV mortality benefit across EF range |
| 30th Aug 2022 7:00 am |
RNS |
Farxiga reduced risk of CV death or worsening HF |
| 25th Aug 2022 7:10 am |
RNS |
Ultomiris approved in Japan for gMG |
| 25th Aug 2022 7:05 am |
RNS |
Tagrisso approved in Japan for early lung cancer |
| 25th Aug 2022 7:00 am |
RNS |
Lynparza approved in Japan for early breast cancer |
| 16th Aug 2022 7:00 am |
RNS |
Lynparza granted FDA priority review for PROpel |
| 15th Aug 2022 7:00 am |
RNS |
Enhertu improved PFS in mBC in DESTINY-Breast02 |
| 12th Aug 2022 7:00 am |
RNS |
Enhertu approved in US for HER2-mutant NSCLC |
| 11th Aug 2022 7:00 am |
RNS |
Acquisition of TeneoTwo completed |
| 8th Aug 2022 7:10 am |
RNS |
Enhertu approved in the US for HER2-low mBC |
| 4th Aug 2022 7:00 am |
RNS |
Lynparza approved in EU for early breast cancer |
| 1st Aug 2022 5:00 pm |
RNS |
Director/PDMR Shareholding |
| 1st Aug 2022 3:05 pm |
RNS |
Director/PDMR Shareholding |
| 1st Aug 2022 3:00 pm |
RNS |
Total Voting Rights |
| 29th Jul 2022 7:01 am |
RNS |
Chair succession |
